Related Experiment Video
Updated: Jul 20, 2026
13:35
A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
Published on: March 1, 2018
[Accidental amphetamine poisoning in an 11-month-old boy]
Summary
Accidental ecstasy (MDMA) poisoning in infants is a growing concern due to household drug use. This case highlights unusual neurological symptoms in an infant, emphasizing the need for awareness and prompt toxicological screening.
Area of Science:
- Pediatric Toxicology
- Neuroscience
- Public Health
Background:
- Rising illicit drug use in France increases risks of accidental pediatric poisoning.
- Ecstasy (MDMA) consumption within households poses a risk to young children and infants.
- Accidental ingestion of ecstasy tablets by infants can lead to severe health consequences.
Observation:
- An 11-month-old infant presented with acute agitation, eye rolling, and unreactive mydriasis.
- Neurological causes were systematically excluded to investigate the symptoms.
- Toxicological analysis confirmed intoxication with an amphetamine, specifically MDMA.
Findings:
- The infant's presentation included atypical neurological symptoms suggestive of toxic exposure.
- Rapid identification of MDMA as the causative agent was crucial for management.
- The infant showed a favorable clinical progression within 24 hours.
Implications:
- This case underscores the emerging threat of pediatric ecstasy intoxication.
- Healthcare providers should consider toxicological screening for infants with unexplained neurological symptoms.
- Public health initiatives are needed to prevent accidental exposure in domestic settings.
Related Concept Videos
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:26Pharmaceutical Poisoning: Potential Scenarios
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
01:26Pharmaceutical Poisoning: Treatment Strategies
Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...